Latanoprost/timolol fixed combination for the treatment of glaucoma

Bibliography

• Quigley HA. Glaucoma. Lancet 2011;377:1367-77
   PubMed Web of Science ®Google Scholar
• Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006;90:262-7
   PubMed Web of Science ®Google Scholar
• European Glaucoma Society. Terminology and guidelines for glaucoma. 3rd edition. Dogma Srl; Savona, Italy; 2008
   Google Scholar
• Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:701-13
   PubMed Web of Science ®Google Scholar
• Kass MA, Gordon MO, Gao F, et al. Delaying treatment of ocular hypertension: the ocular hypertension treatment study. Arch Ophthalmol 2010;128:276-87
   PubMedGoogle Scholar
• Leske MC, Heijl A, et al. Early Manifest Glaucoma Trial Group. Factors for glaucoma progression and the effect of treatment: the Early Manifest Glaucoma Trial. Arch Ophthalmol 2003;121:48-56
   PubMed Web of Science ®Google Scholar
• The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7, the relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000;130:429-40
   PubMed Web of Science ®Google Scholar
• Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol 1998;126:487-97
   PubMed Web of Science ®Google Scholar
• American Academy of Ophthalmology. Primary open-angle glaucoma: preferred Practice Pattern. American Academy of Ophthalmology; San Francisco; 2005
   Google Scholar
• Konstas AGP, Mikropoulos D, Stewart WC. Fixed combination therapies in glaucoma. In: Shaarawy T, Hitchings R, Sherwood M, Crowston J, editors, Glaucoma. Elsevier, USA; 2009. p. 565-75
   Google Scholar
• Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007;120:713-19
   PubMed Web of Science ®Google Scholar
• Konstas AGP, Kozobolis VP, Tersis I, et al. The efficacy and safety of the timolol/dorzolamide fixed combination versus latanoprost in exfoliation glaucoma. Eye 2003;17:41-6
   PubMed Web of Science ®Google Scholar
• Henderer JD, Wilson RP, Moster MR, et al. Timolol/dorzolamide combination therapy as initial treatment for intraocular pressure over 30 mm Hg. J Glaucoma 2005;14:267-70
   PubMed Web of Science ®Google Scholar
• Konstas AGP, Quaranta L, Katsanos A, et al. Fixed combination therapies in glaucoma. In: Shaarawy T, Hitchings R, Sherwood M, Crowston J, editors, Glaucoma. Elsevier, USA; 2013. In press
   Google Scholar
• Fechtner RD, Realini T. Fixed combinations of topical glaucoma medications. Curr Opin Ophthalmol 2004;15:132-5
   PubMedGoogle Scholar
• Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs 2002;62:443-62
   PubMed Web of Science ®Google Scholar
• Whitson JT. Glaucoma: a review of adjunctive therapy and new management strategies. Expert Opin Pharmacother 2007;8:3237-49
   PubMed Web of Science ®Google Scholar
• Stewart WC, Konstas AG, Nelson LA, Kruft B. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines. Ophthalmology 2008;115:1117-1122.e1
   PubMed Web of Science ®Google Scholar
• Konstas AG, Boboridis K, Tzetzi D, et al. Twenty-four-hour control with latanoprost-timolol-fixed combination therapy vs latanoprost therapy. Arch Ophthalmol 2005;123:898-902
   PubMed Web of Science ®Google Scholar
• Konstas AG, Lake S, Economou AI, et al. 24-Hour control with a latanoprost-timolol fixed combination vs timolol alone. Arch Ophthalmol 2006;124:1553-7
   PubMed Web of Science ®Google Scholar
• Quaranta L, Katsanos A, Russo A, Riva I. 24-hour intraocular pressure and ocular perfusion pressure in glaucoma. Surv Ophthalmol 2013;58:26-41
   PubMed Web of Science ®Google Scholar
• Konstas AG, Mikropoulos D, Dimopoulos AT, et al. Second-line therapy with dorzolamide/timolol or latanoprost/timolol fixed combination versus adding dorzolamide/timolol fixed combination to latanoprost monotherapy. Br J Ophthalmol 2008;92:1498-502
   PubMed Web of Science ®Google Scholar
• Konstas AG, Pikilidou MI, Tsironi S, et al. 24-hour intraocular pressure and blood pressure levels with latanoprost/timolol fixed combination versus timolol. Curr Eye Res 2009;34:369-77
   PubMed Web of Science ®Google Scholar
• Konstas AG, Mikropoulos DG, Embeslidis TA, et al. 24-h Intraocular pressure control with evening-dosed travoprost/timolol, compared with latanoprost/timolol, fixed combinations in exfoliative glaucoma. Eye 2010;24:1606-13
   PubMed Web of Science ®Google Scholar
• Eren MH, Gungel H, Altan C, et al. Comparison of dorzolamide/timolol and latanoprost/timolol fixed combinations on diurnal intraocular pressure control in primary open-angle glaucoma. J Ocul Pharmacol Ther 2012;28:381-6
   Google Scholar
• Lichter PR, Musch DC, Gillespie BW. CIGTS Study Group. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology 2001;108:1943-53
   PubMed Web of Science ®Google Scholar
• Konstas AGP, Haidich AB, Rossetti L, Webers CM. Prostaglandin-timolol fixed combinations efficacy: myth or reality? Editorial. Eur J Ophthalmol 2012;22:1-4
   PubMed Web of Science ®Google Scholar
• Tsai JC. A comprehensive perspective on patient adherence to topical glaucoma therapy. Ophthalmology 2009;116:S30-6
   PubMedGoogle Scholar
• DiMatteo MR, Giordani PJ, Lepper HS, Croghan TW. Patient adherence and medical treatment outcomes: a meta-analysis. Med Care 2002;40:794-811
   PubMed Web of Science ®Google Scholar
• Sewitch MJ, Abrahamowicz M, Barkun A, et al. Patient nonadherence to medication in inflammatory bowel disease. Am J Gastroenterol 2003;98:1535-44
   PubMed Web of Science ®Google Scholar
• Schwartz GF, Quigley HA. Adherence and persistence with glaucoma therapy. Surv Ophthalmol 2008;53(Suppl1):S57-68
   PubMed Web of Science ®Google Scholar
• Tsai JC, McClure CA, Ramos SE, et al. Compliance barriers in glaucoma: a systematic classification. J Glaucoma 2003;12:393-8
   PubMed Web of Science ®Google Scholar
• Chrysant SG. Using fixed-dose combination therapies to achieve blood pressure goals. Clin Drug Investig 2008;28:713-34
   PubMed Web of Science ®Google Scholar
• DiMatteo MR. Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research. Med Care 2004;42:200-9
   PubMed Web of Science ®Google Scholar
• Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296-310
   PubMed Web of Science ®Google Scholar
• Olthoff CM, Schouten JSAG, Vandeborne B, Webers C. Noncom pliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension. Ophthalmology 2005;112:953-61
   PubMed Web of Science ®Google Scholar
• Okeke CO, Quigley HA, Jampel HD, et al. Adherence with topical glaucoma medication monitored electronically the Travatan Dosing Aid study. Ophthalmology 2009;116:191-9
   PubMed Web of Science ®Google Scholar
• Hermann MM, Papaconstantinou D, Muether PS, et al. Adherence with brimonidine in patients with glaucoma aware and not aware of electronic monitoring. Acta Ophthalmol 2011;89:e300-5
   PubMed Web of Science ®Google Scholar
• Gurwitz JH, Glynn RJ, Monane M, et al. Treatment for glaucoma: adherence by the elderly. Am J Public Health 1993;83:711-16
   PubMed Web of Science ®Google Scholar
• Robin AL, Covert D. Does adjunctive glaucoma therapy affect adherence to the initial primary therapy? Ophthalmology 2005;112:863-8
   PubMed Web of Science ®Google Scholar
• Boboridis KG, Konstas AGP, Toumanidou V, et al. A 6-Month, observational trial investigating with electronic monitoring the level of adherence and ocular surface health with latanoprost/timolol fixed versus latanoprost and timolol unfixed therapy in glaucoma. Invest Ophthalmol Vis Sci 2012;53:E-Abstract 5097
   Google Scholar
• Francis BA, Du LT, Berke S, et al. Comparing the fixed combination dorzolamide-timolol (Cosopt®) to concomitant administration of 2% dorzolamide (Trusopt®) and 0.5% timolol – a randomized controlled study and a replacement study. J Clin Pharm Ther 2004;29:375-80
   PubMed Web of Science ®Google Scholar
• Aptel F, Cucherat M, Denis P. Efficacy and tolerability of prostaglandin-timolol fixed combinations: a meta-analysis of randomized clinical trials. Eur J Ophthalmol 2012;22:5-18
   PubMed Web of Science ®Google Scholar
• Quaranta L, Biagioli E, Riva I, et al. Prostaglandin analogs and timolol-fixed versus unfixed combinations or monotherapy for open-angle glaucoma: a systematic review and meta-analysis. J Ocul Pharmacol Ther 2013;29:382-9
   PubMed Web of Science ®Google Scholar
• Baudouin C, Labbé A, Liang H, et al. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res 2010;29:312-34
   PubMed Web of Science ®Google Scholar
• Ammar AD, Kahook YM. Effects of benzalconium chloride- or polyquad-preserved fixed combination glaucoma medications on human trabecular meshwork cells. Mol Vis 2011;17:1806-13
   PubMed Web of Science ®Google Scholar
• Broadway DC, Grierson I, O'Brien C, et al. Adverse effects of topical antiglaucoma medication. II. The outcome of filtration surgery. Arch Ophthalmol 1994;112:1446-54
   PubMed Web of Science ®Google Scholar
• Lavin MJ, Wormald RP, Migdal CS, et al. The influence of prior therapy on the success of trabeculectomy. Arch Ophthalmol 1990;108:1543-8
   PubMed Web of Science ®Google Scholar
• Katz G, Springs CL, Craven ER, Montecchi-Palmer M. Ocular surface disease in patients with glaucoma or ocular hypertension treated with either BAK-preserved latanoprost or BAK-free travoprost. Clin Ophthalmol 2010;4:1253-61
   PubMedGoogle Scholar
• Konstas AGP, Mikropoulos D, Haidich AB, et al. Twenty-four-hour intraocular pressure control with the travoprost/timolol maleate fixed combination compared with travoprost when both are dosed in the evening in primary open-angle glaucoma. Br J Ophthalmol 2009;93:481-5
   PubMed Web of Science ®Google Scholar
• Konstas AGP, Holló G, Mikropoulos DG, et al. Twenty-four-hour intraocular pressure control with bimatoprost and the bimatoprost/timolol fixed combination administered in the morning, or evening in exfoliative glaucoma. Br J Ophthalmol 2010;94:209-13
   PubMed Web of Science ®Google Scholar
• Novack GD, Evans R. Commercially available ocular hypotensive products: preservative concentration, stability, storage, and in-life utilization. J Glaucoma 2001;10:483-6
   PubMed Web of Science ®Google Scholar
• Camras CB, Bito LZ, Eakins KE. Reduction of intraocular pressure by prostaglandins applied topically to the eyes of conscious rabbits. Invest Ophthalmol Vis Sci 1977;16:1125-34
   PubMed Web of Science ®Google Scholar
• Resul B, Stjernschantz J, Selén G, Bito L. Structure-activity relationships and receptor profiles of some ocular hypotensive prostanoids. Surv Ophthalmol 1997;41:S47-52
   PubMed Web of Science ®Google Scholar
• Johnson TV, Fan S, Zhan G, et al. Efficacy and mechanisms of intraocular pressure reduction with latanoprost and timolol in participants with ocular hypertension: a comparison of 1 and 6 weeks of treatment. J Glaucoma 2010;19:356-64
   Google Scholar
• Stewart WC. Perspectives in the medical treatment of glaucoma. Curr Opin Ophthalmol 1999;10:99-108
   Google Scholar
• Toris CB, Camras CB, Yablonski ME. Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes. Ophthalmology 1993;100:1297-304
   PubMed Web of Science ®Google Scholar
• Ziai N, Dolan JW, Kacere RD, Brubaker RF. The effects on aqueous dynamics of PhXA41, a new prostaglandin F2 alpha analogue, after topical application in normal and ocular hypertensive human eyes. Arch Ophthalmol 1993;111:1351-8
   PubMed Web of Science ®Google Scholar
• Toris CB, Gabelt BT, Kaufman PL. Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Surv Ophthalmol 2008;53:S107-20
   PubMed Web of Science ®Google Scholar
• Perry CM, McGavin JK, Culy CR, Ibbotson T. Latanoprost: an update of its use in glaucoma and ocular hypertension. Drugs Aging 2003;20:597-630
   PubMed Web of Science ®Google Scholar
• Basu S, Sjöquist B, Stjernschantz J, Resul B. Corneal permeability to and ocular metabolism of phenyl substituted prostaglandin esters in vitro. Prostaglandins Leukot Essent Fatty Acids 1994;50:161-8
   PubMed Web of Science ®Google Scholar
• Digiuni M, Fogagnolo P, Rossetti L. A review of the use of latanoprost for glaucoma since its launch. Expert Opin Pharmacother 2012;13:723-45
   PubMedGoogle Scholar
• Sjöquist B, Stjernschantz J. Ocular and systemic pharmacokinetics of latanoprost in humans. Surv Ophthalmol 2002;47:S6-12
   PubMed Web of Science ®Google Scholar
• USPI for Xalatan®. Available from: http://www.xalatan.com/content/uspi-xalatan.pdf
   Google Scholar
• Konstas AG, Maltezos AC, Gandi S, et al. Comparison of 24-hour intraocular pressure reduction with two dosing regimens of latanoprost and timolol maleate in patients with primary open-angle glaucoma. Am J Ophthalmol 1999;128:15-20
   PubMed Web of Science ®Google Scholar
• Larsson LI. Intraocular pressure over 24 hours after single-dose administration of latanoprost 0.005% in healthy volunteers. A randomized, double-masked, placebo controlled, cross-over single center study. Acta Ophthalmol Scand 2001;79:567-71
   Google Scholar
• Rácz P, Ruzsonyi MR, Nagy ZT, et al. Around-the-clock intraocular pressure reduction with once-daily application of latanoprost by itself or in combination with timolol. Arch Ophthalmol 1996;114:268-73
   PubMed Web of Science ®Google Scholar
• Alm A, Stjernschantz J; the Scandinavian Latanoprost Study Group. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning: a comparison with timolol. Ophthalmology 1995;102:1743-52
   PubMed Web of Science ®Google Scholar
• Brooks AM, Gillies WE. Ocular beta-blockers in glaucoma management. Clinical pharmacological aspects. Drugs Aging 1992;2:208-21
   PubMed Web of Science ®Google Scholar
• Bartels SP, Roth HO, Jumblatt MM, Neufeld AH. Pharmacological effects of topical timolol in the rabbit eye. Invest Ophthalmol Vis Sci 1980;19:1189-97
   PubMed Web of Science ®Google Scholar
• Feldman RM. An evaluation of the fixed-combination of latanoprost and timolol for use in open-angle glaucoma and ocular hypertension. Expert Opin Pharmacother 2004;5:909-21
   PubMed Web of Science ®Google Scholar
• Amyot M, Blondeau P. Timolol maleate. Pharmacology and review of the literature. Can J Ophthalmol 1979;14:208-14
   PubMed Web of Science ®Google Scholar
• Calissendorff B, Sjöquist B, Högberg G, Grunge-Lowerud A. Bioavailability in the human eye of a fixed combination of latanoprost and timolol compared to monotherapy. J Ocul Pharmacol Ther 2002;18:127-31
   PubMed Web of Science ®Google Scholar
• Villumsen J, Alm A. The effect of adding prostaglandin F2 alpha-isopropylester to timolol in patients with open angle glaucoma. Arch Ophthalmol 1990;108:1102-5
   PubMedGoogle Scholar
• Lee PY, Shao H, Camras CB, Podos SM. Additivity of prostaglandin F2 alpha-1-isopropyl ester to timolol in glaucoma patients. Ophthalmology 1991;98:1079-82
   PubMed Web of Science ®Google Scholar
• Konstas AG, Maskaleris G, Gratsonidis S, Sardelli C. Compliance and viewpoint of glaucoma patients in Greece. Eye 2000;14:752-6
   PubMed Web of Science ®Google Scholar
• Patel SC, Spaeth GL. Compliance in patients prescribed eyedrops for glaucoma. Ophthalmic Surg 1995;26:233-6
   PubMedGoogle Scholar
• Hamacher T, Schinzel M, Schölzel-Klatt A, et al. Short term efficacy and safety in glaucoma patients changed to the latanoprost 0.005%/timolol maleate 0.5% fixed combination from monotherapies and adjunctive therapies. Br J Ophthalmol 2004;88:1295-8
   PubMed Web of Science ®Google Scholar
• Higginbotham EJ, Feldman R, Stiles M, Dubiner H; Fixed Combination Investigative Group. Latanoprost and timolol combination therapy vs monotherapy: one-year randomized trial. Arch Ophthalmol 2002;120:915-22
   PubMed Web of Science ®Google Scholar
• Stewart WC, Stewart JA, Day D, Sharpe ED. Efficacy and safety of timolol maleate/latanoprost fixed combination versus timolol maleate and brimonidine given twice daily. Acta Ophthalmol Scand 2003;81:242-6
   PubMedGoogle Scholar
• Tabet R, Stewart WC, Feldman R, Konstas AG. A review of additivity to prostaglandin analogs: fixed and unfixed combinations. Surv Ophthalmol 2008;53:S85-92
   PubMed Web of Science ®Google Scholar
• Inoue K, Fujimoto T, Higa R, et al. Efficacy and safety of a switch to latanoprost 0.005% + timolol maleate 0.5% fixed combination eye drops from latanoprost 0.005% monotherapy. Clin Ophthalmol 2012;6:771-5
   PubMedGoogle Scholar
• Cheng JW, Cheng SW, Gao LD, et al. Intraocular pressure-lowering effects of commonly used fixed-combination drugs with timolol: a systematic review and meta-analysis. PLoS ONE 2012;7:e45079
   PubMed Web of Science ®Google Scholar
• Cheng JW, Cai JP, Li Y, Wei RL. A meta-analysis of topical prostaglandin analogs in the treatment of chronic angle-closure glaucoma. J Glaucoma 2009;18:652-7
   PubMed Web of Science ®Google Scholar
• Cheng JW, Cai JP, Wei RL. Meta-analysis of medical intervention for normal tension glaucoma. Ophthalmology 2009;116:1243-9
   PubMed Web of Science ®Google Scholar
• Larrson LI. Effect on intraocular pressure during 24 hours after repeated administration of the fixed combination of latanoprost 0.005% and timolol 0.5% in patients with ocular hypertension. J Glaucoma 2001;10:109-14
   Google Scholar
• Webers CA, Beckers HJ, Zeegers MP, et al. The intraocular pressure-lowering effect of prostaglandin analogs combined with topical β-blocker therapy: a systematic review and meta-analysis. Ophthalmology 2010;117:2067-74. e1-6
   PubMedGoogle Scholar
• Schwenn O, Heckmann B, Guzy C, Miller PJ. Long-term effect of latanoprost/timolol fixed combination in patients with glaucoma or ocular hypertension: a prospective, observational, noninterventional study. BMC Ophthalmol 2010;10:1-9
   Google Scholar
• Diestelhorst M, Almegård B. Comparison of two fixed combinations of latanoprost and timolol in open-angle glaucoma. Graefe's Arch Clin Exp Ophthalmol 1998;236:577-81
   PubMed Web of Science ®Google Scholar
• Pfeiffer N; European Latanoprost Fixed Combination Study Group. A comparison of the fixed combination of latanoprost and timolol with its individual components. Graefes Arch Clin Exp Ophthalmol 2002;240:893-9
   PubMed Web of Science ®Google Scholar
• Higginbotham EJ, Olander KW, Kim EE, et al. Fixed combination of latanoprost and timolol vs individual components for primary open-angle glaucoma or ocular hypertension: a randomized, double-masked study. Arch Ophthalmol 2010;128:165-72
   PubMed Web of Science ®Google Scholar
• Lazaridou MN, Montgomery DM, Ho WO, Jaberoo D. Changes in intraocular pressure following a switch from latanoprost monotherapy to latanoprost/timolol fixed combination therapy in patients with primary open-angle glaucoma or ocular hypertension: results from a clinical practice database. Curr Med Res Opin 2008;24:2725-8
   PubMed Web of Science ®Google Scholar
• Centofanti M, Oddone F, Vetrugno M, et al. Efficacy of the fixed combinations of bimatoprost or latanoprost plus timolol in patients uncontrolled with prostaglandin monotherapy: a multicenter, randomized, investigator-masked, clinical study. Eur J Ophthalmol 2009;19:66-71
   PubMed Web of Science ®Google Scholar
• Palmberg P, Kim EE, Kwok KK, Tressler CS; Canada and United States Fixed Combination Latanoprost/Timolol Study Group. A 12-week, randomized, double-masked study of fixed combination latanoprost/timolol versus latanoprost or timolol monotherapy. Eur J Ophthalmol 2010;20:708-18
   PubMed Web of Science ®Google Scholar
• Konstas AG, Nakos E, Tersis I, et al. Comparison of once-daily morning vs evening dosing of concomitant latanoprost/timolol. Am J Ophthalmol 2002;133:753-7
   PubMed Web of Science ®Google Scholar
• Takmaz T, Aşik S, Kürkçüoğlu P, et al. Comparison of intraocular pressure lowering effect of once daily morning vs evening dosing of latanoprost/timolol maleate combination. Eur J Ophthalmol 2008;18:60-5
   PubMed Web of Science ®Google Scholar
• Varma R, Hwang LJ, Grunden JW, Bean GW. Using diurnal intraocular pressure fluctuation to assess the efficacy of fixed-combination latanoprost/timolol versus latanoprost or timolol monotherapy. Br J Ophthalmol 2010;94:80-4
   PubMed Web of Science ®Google Scholar
• Konstas AG, Quaranta L, Mikropoulos DG, et al. Peak intraocular pressure and glaucomatous progression in primary open-angle glaucoma. J Ocul Pharmacol Ther 2012;28:26-32
   PubMed Web of Science ®Google Scholar
• Shin DH, Feldman RM, Sheu WP; Fixed Combination Latanoprost/Timolol Study Group. Efficacy and safety of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure. Ophthalmology 2004;111:276-82
   PubMed Web of Science ®Google Scholar
• Miglior S, Grunden JW, Kwok K; Xalacom/Cosopt European Study Group. Efficacy and safety of fixed combinations of latanoprost/timolol and dorzolamide/timolol in open-angle glaucoma or ocular hypertension. Eye 2010;24:1234-42
   PubMed Web of Science ®Google Scholar
• Cvenkel B, Stewart JA, Nelson LA, Stewart WC. Dorzolamide/timolol fixed combination versus latanoprost/timolol fixed combination in patients with primary open-angle glaucoma or ocular hypertension. Curr Eye Res 2008;33:163-8
   PubMed Web of Science ®Google Scholar
• Konstas AG, Kozobolis VP, Lallos N, et al. Daytime diurnal curve comparison between the fixed combinations of latanoprost 0.005%/timolol 0.5% and dorzolamide 2%/timolol 0.5%. Eye 2004;18:1264-9
   PubMed Web of Science ®Google Scholar
• Januleviciene I, Ehrlich R, Siesky B, et al. Visual function, optic nerve structure, and ocular blood flow parameters after 1 year of glaucoma treatment with fixed combinations. Eur J Ophthalmol 2009;19:790-7
   PubMed Web of Science ®Google Scholar
• Hommer A, Sperl P, Resch H, et al. A double-masked randomized crossover study comparing the effect of latanoprost/timolol and brimonidine/timolol fixed combination on intraocular pressure and ocular blood flow in patients with primary open-angle glaucoma or ocular hypertension. J Ocul Pharmacol Ther 2012;28:569-75
   PubMed Web of Science ®Google Scholar
• Magacho L, Reis R, Shetty RK, et al. Efficacy of latanoprost or fixed-combination latanoprost-timolol in patients switched from a combination of timolol and a nonprostaglandin medication. Ophthalmology 2006;113:442-5
   Google Scholar
• Martinez A, Sanchez M. A comparison of the safety and intraocular pressure lowering of bimatroprost/timolol fixed combination versus latanoprost/timolol fixed combination in patients with open-angle glaucoma. Curr Med Res Opin 2007;23:1025-32
   PubMed Web of Science ®Google Scholar
• Martinez A, Sanchez M. Bimatoprost/timolol fixed combination vs latanoprost/timolol fixed combination in open-angle glaucoma patients. Eye 2009;23:810-18
   PubMed Web of Science ®Google Scholar
• Topouzis F, Melamed S, Danesh-Meyer H, et al. A 1-year study to compare the efficacy and safety of once-daily travoprost 0.004%/timolol 0.5% to once-daily latanoprost 0.005%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension. Eur J Ophthalmol 2007;17:183-90
   PubMed Web of Science ®Google Scholar
• Franks WA, Renard JP, Cunliffe IA, Rojanapongpun P. A 6-week, double- masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0.005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension. Clin Ther 2006;28:332-9
   PubMed Web of Science ®Google Scholar
• Centofanti M, Oddone F, Gandolfi S, et al. Comparison of Travoprost and Bimatoprost plus timolol fixed combinations in open-angle glaucoma patients previously treated with latanoprost plus timolol fixed combination. Am J Ophthalmol 2010;150:575-80
   PubMed Web of Science ®Google Scholar
• Alm A, Grierson I, Shields MB. Side effects associated with prostaglandin analog therapy. Surv Ophthalmol 2008;53:S93-105
   PubMed Web of Science ®Google Scholar
• Pfeiffer N; the German Latanoprost Fixed Combination Study Group. A comparison of the fixed combination of latanoprost and timolol with its individual components in patients with glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci 2000;41:S754
   Google Scholar
• Fechtner RD, Khouri AS, Zimmerman TJ, et al. Anterior uveitis associated with latanoprost. Am J Ophthalmol 1998;126:37-41
   PubMed Web of Science ®Google Scholar
• Schumer RA, Camras CB, Mandahl AK. Putative side effects of prostaglandin analogs. Surv Ophthalmol 2002;47(Suppl 1):S219-30
   Web of Science ®Google Scholar
• Horsley MB, Chen TC. The use of prostaglandin analogs in the uveitic patient. Semin Ophthalmol 2011;26:285-9
   PubMed Web of Science ®Google Scholar
• Markomichelakis NN, Kostakou A, Halkiadakis I, et al. Efficacy and safety of latanoprost in eyes with uveitic glaucoma. Graefes Arch Clin Exp Ophthalmol 2009;247:775-80
   PubMed Web of Science ®Google Scholar
• Alm A, Grunden JW, Kwok KK. Five-year, multicenter safety study of fixed-combination latanoprost/timolol (Xalacom) for open-angle glaucoma and ocular hypertension. J Glaucoma 2011;20:215-22
   PubMed Web of Science ®Google Scholar
• Shah M, Lee G, Lefebvre DR, et al. A cross-sectional survey of the association between bilateral topical prostaglandin analogue use and ocular adnexal features. PLoS ONE 2013;8:e61638
   PubMed Web of Science ®Google Scholar
• Jayaprakasam A, Ghazi-Nouri S. Periorbital fat atrophy - an unfamiliar side effect of prostaglandin analogues. Orbit 2010;29:357-9
   PubMedGoogle Scholar
• Choi HY, Lee JE, Lee JW, et al. In vitro study of antiadipogenic profile of latanoprost, travoprost, bimatoprost, and tafluprost in human orbital preadiopocytes. J Ocul Pharmacol Ther 2012;28:146-52
   PubMed Web of Science ®Google Scholar
• Quaranta L, Gandolfo F, Turano R, et al. Effects of topical hypotensive drugs on circadian IOP, blood pressure, and calculated diastolic ocular perfusion pressure in patients with glaucoma. Invest Ophthalmol Vis Sci 2006;47:2917-23
   PubMed Web of Science ®Google Scholar
• Taniguchi T, Kitazawa Y. The potential systemic effect of topically applied beta-blockers in glaucoma therapy. Curr Opin Ophthalmol 1997;8:55-8
   PubMedGoogle Scholar
• Larsson LI. Effect on intraocular pressure during 24 hours after repeated administration of the fixed combination of latanoprost 0.005% and timolol 0.5% in patients with ocular hypertension. J Glaucoma 2001;10:109-14
   PubMed Web of Science ®Google Scholar